Patient Square Capital LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001819257

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q4 2024 · 20 positions · Total reported value $267.37M · Top-10 concentration 89.8% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 69.0% · 6 new · 8 cut · 6 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q4 2024 13F filing, Patient Square Capital LP disclosed 20 equity positions with a combined reported value of $267.37M. The filing implies a focused portfolio: its ten largest positions account for 89.8% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q4 2024 were ROIV ($147.64M), LQDA ($21.88M), INSM ($21.21M). By sector, the heaviest allocations are Health Care 92.2%, Industrials 3.9%. Versus the prior quarter, allocation shifted toward Other (+3.7pp) and away from Health Care (-3.6pp).

Versus the prior quarter, Patient Square Capital LP opened 6 new positions, trimmed 8 and fully exited 6, a turnover rate of 69.0% of positions. The portfolio's overlap with the prior quarter was 55% of names.

The largest new positions opened in Q4 2024 were ITCI ($6.01M), GERN ($4.68M), AGIO ($4.00M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q4 2024)

  • ITCI INTRA CELLULAR THERAPIES INC · $6.01M
  • GERN GERON CORP · $4.68M
  • AGIO AGIOS PHARMACEUTICALS INC · $4.00M
  • IRON DISC MEDICINE INC · $3.58M
  • SWTX SPRINGWORKS THERAPEUTICS INC · $3.37M
  • ALLO ALLOGENE THERAPEUTICS INC · $3.17M
  • MIRM MIRUM PHARMACEUTICALS INC · $2.68M
  • ARVN ARVINAS INC · $1.66M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Patient Square Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Patient Square Capital LP is a Menlo Park, CA-based investment firm founded by David Goel and Stephen Mandel Jr. with approximately $17.5 billion in assets under management.

Investment Approach

They employ a long-term, concentrated investment strategy focusing on high-quality companies with strong competitive advantages.

Asset Classes

Primarily invests in US equities, as evidenced by their SEC Form 13F filings.

Notable Facts

Founded in 2016, known for activist investment style, sometimes taking significant positions in companies and advocating for changes.

Key People

Founded by David Goel and Stephen Mandel Jr. (co-founder of Lone Pine Capital).

For official disclosures, refer to the firm's SEC filings.

Sector Allocation

Health Care 92.2%
Other 3.9%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 12.48M $147.64M 55.22%
55.22%
Add
2 1.86M $21.88M 8.18%
8.18%
Reduce
3 307.17K $21.21M 7.93%
7.93%
Add
4 878.90K $10.70M 4.00%
4.00%
Add
5 1.41M $10.51M 3.93%
3.93%
Add
6 446.30K $8.41M 3.15%
3.15%
Add
7 71.99K $6.01M 2.25%
2.25%
New
8 224.04K $5.04M 1.89%
1.89%
Add
9 1.32M $4.68M 1.75%
1.75%
New
10 470.92K $4.02M 1.50%
1.50%
Add
11 121.73K $4.00M 1.50%
1.50%
New
12 207.60K $3.98M 1.49%
1.49%
Reduce
13 56.40K $3.58M 1.34%
1.34%
New
14 93.14K $3.37M 1.26%
1.26%
New
15 1.49M $3.17M 1.19%
1.19%
New
16 64.90K $2.68M 1.00%
1.00%
New
17 215.98K $2.52M 0.94%
0.94%
Add
18 86.63K $1.66M 0.62%
0.62%
New
19 32.00K $1.38M 0.52%
0.52%
New
20 105.06K $939.21K 0.35%
0.35%
Add

FAQ

What did Patient Square Capital LP buy in 2024-Q4?

In its 2024-Q4 13F filing, Patient Square Capital LP reported 20 equity positions worth $267.37M in aggregate; its largest disclosed positions were ROIV ($147.64M), LQDA ($21.88M), INSM ($21.21M).

How large is Patient Square Capital LP's portfolio?

Patient Square Capital LP reported $267.37M of long equity holdings across 20 positions as of 2024-Q4. Top-10 holdings account for 89.8% of reported value.

What is Patient Square Capital LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/patient-square-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →